+

WO1998009638A1 - INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49 - Google Patents

INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49 Download PDF

Info

Publication number
WO1998009638A1
WO1998009638A1 PCT/US1997/015586 US9715586W WO9809638A1 WO 1998009638 A1 WO1998009638 A1 WO 1998009638A1 US 9715586 W US9715586 W US 9715586W WO 9809638 A1 WO9809638 A1 WO 9809638A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
human
cells
protein
cell
Prior art date
Application number
PCT/US1997/015586
Other languages
English (en)
Inventor
Howard R. Katz
Jonathan P. Arm
Maria C. Castells
K. Frank Austen
Original Assignee
The Brigham And Women's Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women's Hospital, Inc. filed Critical The Brigham And Women's Hospital, Inc.
Priority to AU44103/97A priority Critical patent/AU4410397A/en
Publication of WO1998009638A1 publication Critical patent/WO1998009638A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the rat monoclonal antibody (mAb) 1 B23.1 recognizes an epitope expressed on an ⁇ 49-kDa glycoprotein on the surface of mouse mast cells that is synthesized from an intracellular 37-kDa protein precursor (Katz et al . , 1989, J. Immunol. 142:919-926). Immunoaffinity purification of a cell-surface protein from mast cells with mAb B23.1, determination of its amino-terminal amino acid sequence, and screening of a mast cell cDNA library with oligonucleotides encoding the amino-terminal sequence provided three cDNAs that encode this amino-terminal amino acid sequence (Arm et al . ,
  • BSA bovine serum albumin
  • Fc ⁇ R Fc receptor for IgA
  • FceRI high affinity Fc receptor for IgE
  • FC ⁇ 2R FC receptor for IgG
  • Fc ⁇ RIIbl and Fc ⁇ RIIb2 Fc receptors for IgG, type Ilbl and IIb2, respectively
  • FITC fluorescein isothiocyanate
  • H/B/A HBSS containing 0.1% (w/v) BSA and 0.02% (w/v) sodium azide
  • HBSS calcium- and magnesium-free Hanks' Balanced Salt Solution
  • Ig immunoglobulin
  • ITIM immunoreceptor tyrosine-based inhibition motif
  • KIR killer cell inhibitory receptor
  • LT leukotriene
  • mAb monoclonal antibody
  • mBMMC mouse bone marrow-derived mast cells
  • mMIR mouse mast cell inhibitory receptor
  • MHC major histocompatibility complex
  • NK natural killer cell inhibitory receptor
  • gp49A also has 100% amino acid identity with gp49Bl in the transmembrane and 88% identity in the first 34 amino acids of the cytoplasmic domain.
  • the cytoplasmic region of gp49A then diverges for 8 amino acids because of a frameshift in the nucleotide sequence and terminates so that it is 32 amino acids shorter than gp49Bl.
  • gp49 molecules are directly involved in downregulating FceRI -mediated release of proinflammatory mediators from mast cells.
  • relevant molecules include fragments of those sequences and related polypeptides described elsewhere herein. These polypeptides (and non-peptide mimetics) , as well as nucleic acid encoding them, can be used for a variety of therapies, particularly therapies involving control of mast cell activation and control of inflammatory and allergic responses.
  • Mammalian (particularly human) gp49 polypeptides can be used to verify, evaluate or mimic immunological processes, as well as the effect of exogenous substances on such processes .
  • One embodiment of the invention generally features a substantially pure human gp49 polypeptide, particularly polypeptides that are soluble in physiological fluid.
  • polypeptides comprising at least one of the following functional human gp49 domains: a) a human gp49 signal peptide domain; b) a human gp49 C-2 Ig domain; c) a human gp49 transmembrane domain; d) a human gp49 cytoplasmic tail (e.g., polypeptides comprising an ITIM motif of a human gp49 cytoplasmic tail.
  • the gp49 polypeptide includes an amino acid sequence substantially identical to the amino acid sequence shown in Fig. 1 or the amino acid sequence shown in Fig. 2.
  • isolated nucleic acid DNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived.
  • a recombinant nucleic acid could include some or all of the 5' non-coding (e.,g., promoter) sequences which are immediately contiguous to the coding sequence.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
  • mature human gp49 is meant a polypeptide having the sequence shown in FIG's 1 or 2 lacking the leader sequence.
  • Polypeptides substantially identical to mature human gp49 have an amino acid sequence which is at least 85%, preferably 90%, and most preferably 95% or even 99% identical to the amino acid sequence of the gp49 polypeptide of the FIGs .
  • substantially identical is meant a polypeptide or nucleic acid having a sequence that is at least 85%, preferably 90%, and more preferably 95% or more identical to the sequence of the reference amino acid or nucleic acid sequence (e.g. of HM18 or HM43) .
  • the length of the reference polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.
  • the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides .
  • Sequence identity can be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705) .
  • non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence.
  • Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine .
  • a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide.
  • a peptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might also be a 100 amino acid long polypeptide which is 50% identical to the reference polypeptide over its entire length.
  • Polypeptides corresponding to one or more domains of gp49 are also within the scope of the invention.
  • Preferred polypeptides are those which are soluble under normal physiological conditions.
  • soluble fusion proteins in which a full- length form of gp49 or a portion (e.g., one or more domains) thereof is fused to an unrelated protein or polypeptide (i.e., a fusion partner) to create a fusion protein.
  • the invention also features isolated nucleic acid sequences that encode a portion of gp49 and various functional domains of gp49. Also within the invention are nucleic acids encoding polypeptides corresponding to one or more domains of gp49. Preferred nucleic acids encode polypeptides that are soluble under normal physiological conditions. Also within the invention are nucleic acids encoding fusion proteins in which a portion of gp49 or a portion (e.g., one or more domains) thereof is fused to an unrelated protein or polypeptide (i.e., a fusion partner) to create a fusion protein. Encompassed within the invention are nucleic acid sequences that encode forms of gp49 in which sequences are altered or deleted.
  • the nucleic acids of the invention include nucleic acids encoding mature gp49 as well as gp49 polypeptides fused to a polypeptide which facilitates secretion, e.g., a secretory sequence. Such a fused protein is typically referred to as a preprotein.
  • the secretory sequence can be removed by the host cell to form the mature protein.
  • the invention also encompasses nucleic acids that hybridize under stringent conditions to a nucleic acid encoding a gp49 polypeptide.
  • Stringent conditions means hybridization at 50°C in Church buffer (7% SDS, 0.5% NaHP0 4 , lmM EDTA, 1%BSA) and washing at 50°C in 2x SSC.
  • the hybridizing portion of the hybridizing nucleic acids are preferably 20, 30, 50, or 70 bases long.
  • the hybridizing portion of the hybridizing nucleic acid is 95% or even 98% identical to the sequence of a portion of a nucleic acid encoding a gp49 polypeptide.
  • Hybridizing nucleic acids of the type described above can be used as a cloning probe, a primer
  • hybridizing nucleic acids encode a polypeptide having some or all of the biological activities possessed by naturally-occurring gp49.
  • Hybridizing nucleic acids can be splice variants encoded by one of the gp49 genes described herein. Thus, they may encode a protein which is shorter or longer than the various forms of gp49 described herein.
  • Hybridizing nucleic acids may also encode proteins which are related to gp49 (e.g, proteins encoded by genes which include a portion having a relatively high degree of identity to a gp49 gene described herein) .
  • the invention also features substantially pure gp49 polypeptides.
  • polypeptides encompassed within the invention are those corresponding to the extracellular domain, the transmembrane domain, the cytoplasmic domain, and various functional domains of gp49.
  • the invention also encompasses polypeptides and nucleic acids whose sequences are substantially identical to that of a form of gp49 described herein.
  • protein and “polypeptide” is meant any chain of amino acids, regardless of length or post- translational modification (e.g., glycosylation or phosphorylation) .
  • substantially pure is meant a preparation which is at least 60% by weight (dry weight) the compound of interest, i.e., a gp49 polypeptide.
  • the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate standard method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
  • nucleic acid encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA.
  • the nucleic acid may be double-stranded or single-stranded. Where single- stranded, the nucleic acid may be the sense strand or the antisense strand.
  • the polypeptides of the invention include, but are not limited to: recombinant polypeptides, natural polypeptides, and synthetic polypeptides as well as polypeptides which are preproteins or proproteins.
  • polypeptides of the invention can be expressed fused to another polypeptide, e.g., a marker polypeptide or fusion partner.
  • the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.
  • the invention features transformed cells harboring a nucleic acid encompassed by the invention.
  • the invention also features vectors and plasmid which include a nucleic acid of the invention which is properly positioned for expression.
  • transformed cell is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) gp49 polypeptide.
  • positioned for expression is meant that the selected DNA molecule is positioned adjacent to one or more sequence elements which direct transcription and/or translation of the sequence such that the sequence elements can control transcription and/or translation of the selected DNA (i.e., the selected DNA is operably associated with the sequence elements) .
  • Such operably associated elements can be used to facilitate the production of a gp49 polypeptide.
  • the invention also features purified antibodies which specifically bind a gp49 protein or polypeptide.
  • purified antibody is meant an antibody which is at least 60%, by dry weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.
  • the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by dry weight, antibody.
  • telomere binding an antibody that recognizes and binds to a particular antigen, e.g., gp49 polypeptide, but which does not substantially recognize and bind to other molecules in a sample, e.g., a biological sample, which naturally includes gp49.
  • the invention also features antagonists and agonists of gp49.
  • Antagonists can inhibit one or more of the functions of gp49.
  • Suitable antagonists can include large or small molecules, antibodies to gp49, and gp49 polypeptides which compete with a native form of gp49.
  • Agonists of gp49 will enhance or facilitate one or more of the functions of gp49.
  • Suitable agonists can include, for example, large or small molecules and antibodies to gp49.
  • the invention also features a substantially pure polypeptide which includes a first portion and a second portion; the first portion includes a gp49 polypeptide and the second portion includes, e.g.,
  • the invention also features a substantially pure polypeptide which includes a first portion and a second portion; the first portion includes a gp49 polypeptide the said second portion includes a detectable marker.
  • the invention features a recombinant nucleic acid encoding a gp49 polypeptide.
  • the nucleic acid encodes a soluble gp49 polypeptide.
  • the invention also features a nucleic acid encoding a hybrid polypeptide.
  • This hybrid polypeptide includes a first portion and a second portion; the first portion includes a gp49 polypeptide; the second portion includes a FceRI region.
  • the invention also feature a cell which harbors a recombinant nucleic acid encoding a gp49 polypeptide; a vector which includes a nucleic acid encoding a gp49 polypeptide .
  • the invention features an antibody which selectively binds to a gp49 polypeptide.
  • the antibody is a monoclonal antibody.
  • the invention also features a pharmaceutical composition which includes a gp49 polypeptide.
  • the invention features a method for detecting inflammation.
  • This method includes: (a) obtaining a biological sample; (b) contacting the sample with an antibody which selectively binds a gp49 polypeptide; and (c) determining the amount of the antibody selectively bound to said biological sample as a measure of inflammation.
  • the invention features a method for treating inflammation in a patient which includes administering to the patient an agonist of gp49.
  • Specific medical indications include allergic rhinitis, subacute and chronic urticaria, and bronchial asthma.
  • the invention also features administering to the patient a substantially pure gp49 polypeptide capable of inhibiting mast cell activity.
  • nucleic acids encoding a human gp49 polypeptides and fusion polypeptides, as well as cells or vectors comprising the recombinant nucleic acids.
  • the invention also features pharmaceutical compositions comprising the gp49 polypeptides or the nucleic acids.
  • the invention also features methods of treating an undesired immune response (particularly mast cell related diseases) in a patient by administering a mammalian gp49 polypeptide or nucleic acid encoding a mammalian gp49 polypeptide .
  • Other features and advantages of the invention will be apparent from the following detailed descriptions, and from the claims.
  • Fig. 1 is a depiction of the nucleotide and amino acid sequences of a form of human gp49 (HM18) , including a putative signal sequence.
  • Fig. 2 is a depiction of the nucleotide and amino acid sequences of a form of human gp4 (HM43) , including a putative signal sequence.
  • Fig. 3 compares the sequence of HM18 to the sequence of mouse gp41Bl.
  • the invention encompasses, but is not limited to, gp49 proteins and polypeptides that are functionally related to gp49 encoded by the nucleotide sequence of Fig. 1 or Fig. 2.
  • Functionally related proteins and polypeptides include any protein or polypeptide sharing a functional characteristic with gp49, e.g., the ability to affect proliferation, differentiation, survival, apoptosis, or activation of a cell type whose proliferation, differentiation, survival, apoptosis, or activation is affected by gp49.
  • Such functionally related gp49 polypeptides include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the gp49 sequences described herein which result in a silent change, thus producing a functionally equivalent gene product.
  • Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
  • nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine;
  • polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
  • positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • mutant gp49 proteins can be tested for activity
  • site-directed mutations of the gp49 coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the art) to generate mutant gp49s with increased function, e.g., greater stimulation of cell proliferation, or decreased function, e.g., lesser stimulation of cell proliferation.
  • Fig. 4 shows an alignment between the amino acid sequence of human gp49 and murine gp49, which can be used to determine the conserved and variable amino acid positions.
  • conserved residues are not altered.
  • alteration of non-conserved residues are preferably conservative alterations, e.g., a basic amino acid is replaced by a different basic amino acid.
  • non-conservative changes at variable and/or conserved positions it is preferable to make non-conservative changes at variable and/or conserved positions. Deletions at conserved and variable positions can also be used to create altered function variants.
  • N- linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites.
  • a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur (in N-X-S or N-X-T) , and/or an amino acid deletion at the second position of any one or more of such recognition sequences will prevent glycosylation at the modified tripeptide sequence. (See , e.g., Miyajima et al . , EMBO J. 5:1193, 1986) .
  • Preferred gp49 polypeptides are those polypeptides, or variants thereof, which control mast cell activity. In determining whether a particular gp49 polypeptide or variant thereof controls mast cell activity, one can use any assay techniques disclosed herein or in referenced publications. Preferred gp49 polypeptides and variants have 20%, 40%, 50%, 75%, 80%, or even 90% of the activity of the full-length, mature human form of gp49 described herein. Such comparisons are generally based on equal concentrations of the molecules being compared. The comparison can also be based on the amount of protein or polypeptide required to reach 50% of the maximal stimulation obtainable.
  • Polypeptides corresponding to one or more domains of gp49 are those which are soluble under normal physiological conditions.
  • fusion proteins in which a portion (e.g., one or more domains) of gp49 is fused to an unrelated protein or polypeptide (i.e., a fusion partner) to create a fusion protein.
  • the fusion partner can be a moiety selected to facilitate purification, detection, or solubilization, or to provide some other function. Fusion proteins are generally produced by expressing a hybrid gene in which a nucleotide sequence encoding all or a portion of gp49 is joined in- frame to a nucleotide sequence encoding the fusion partner.
  • gp49 Also within the scope of the invention are various soluble forms of gp49.
  • the entire extracellular domain of gp49 or a portion thereof can be expressed on its own or fused to a solubilization partner, e.g., an immunoglobulin.
  • gp49 proteins according to the invention can be produced by transformation (transfection, transduction, or infection) of a host cell with all or part of a gp49-encoding DNA fragment (e.g., the cDNA described herein) in a suitable expression vehicle.
  • suitable expression vehicles include: plasmids, viral particles, and phage.
  • baculovirus expression vectors are suitable.
  • the entire expression vehicle, or a part thereof, can be integrated into the host cell genome.
  • it is desirable to employ an inducible expression vector e.g., the LACSWITCHTM Inducible Expression System (Stratagene ,• LaJolla, CA) .
  • the gp49 protein can be produced in a prokaryotic host (e.g., E. coli or B . subtilis) or in a eukaryotic host (e.g., Saccharomyces or Pichia ; mammalian cells, e.g., COS, NIH 3T3 CHO, BHK, 293, or HeLa cells; or insect cells) .
  • a prokaryotic host e.g., E. coli or B . subtilis
  • a eukaryotic host e.g., Saccharomyces or Pichia ; mammalian cells, e.g., COS, NIH 3T3 CHO, BHK, 293, or HeLa cells; or insect cells.
  • Proteins and polypeptides can also be produced by plant cells.
  • viral expression vectors e.g., cauliflower mosaic virus and tobacco mosaic virus
  • plasmid expression vectors e.g., Ti plasmid
  • Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, MD; also, see, e.g., Ausubel et al . , Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1994) .
  • the methods of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al .
  • expression vehicles may be chosen from those provided, e.g., in Cloning Vectors : A Laboratory Manual (P.H. Pouwels et al . , ' 1985, Supp. 1987) .
  • the host cells harboring the expression vehicle can be cultured in conventional nutrient media adapted as need for activation of a chosen gene, repression of a chosen gene, selection of transformants, or amplification of a chosen gene .
  • pMAMneo provides an RSV-LTR enhancer linked to a dexamethasone- inducible MMTV-LTR promotor, an SV40 origin of replication which allows replication in mammalian systems, a selectable neomycin gene, and SV40 splicing and polyadenylation sites.
  • DNA encoding a gp49 protein would be inserted into the pMAMneo vector in an orientation designed to allow expression. The recombinant gp49 protein would be isolated as described below.
  • Other preferable host cells that can be used in conjunction with the pMAMneo expression vehicle include
  • COS cells and CHO cells (ATCC Accession Nos. CRL 1650 and CCL 61, respectively).
  • Gp49 polypeptides can be produced as fusion proteins.
  • the expression vector pUR278 (Ruther et al . , EMBO J. 2:1791, 1983), can be used to create lacZ fusion proteins.
  • the pGEX vectors can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
  • GST glutathione S-transferase
  • such fusion proteins are soluble and can be easily purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
  • the pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • Autographa californica nuclear polyhidrosis virus (AcNPV) , which grows in Spodoptera frugiperda cells, is used as a vector to express foreign genes.
  • a gp49 coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter, e.g., the polyhedrin promoter.
  • a number of viral -based expression systems can be utilized.
  • the gp49 nucleic acid sequence can be ligated to an adenovirus transcription/translation control complex, e.g. , the late promoter and tripartite leader sequence.
  • This chimeric gene can then be inserted into the adenovirus genome by in vi tro or in vivo recombination. Insertion into a non- essential region of the viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing a gp49 gene product in infected hosts (see, e.g., Logan, Proc.
  • Specific initiation signals may also be required for efficient translation of inserted nucleic acid sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire native gp49 gene or CDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. In other cases, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators (Bittner et al., Methods in Enzymol . 153:516, 1987).
  • a host cell may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
  • Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
  • eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used.
  • mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, choroid plexus cell lines.
  • a gp49 protein can be produced by a stably-transfected mammalian cell line.
  • a number of vectors suitable for stable transfection of mammalian cells are available to the public, see, e.g., Pouwels et al . (supra) ; methods for constructing such cell lines are also publicly available, e.g., in Ausubel et al . (supra) .
  • CDNA encoding the gp49 protein is cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene.
  • DHFR dihydrofolate reductase
  • Integration of the plasmid and, therefore, the gp49 protein-encoding gene into the host cell chromosome is selected for by including 0.01-300 ⁇ M methotrexate in the cell culture medium (as described in Ausubel et al . , supra) . This dominant selection can be accomplished in most cell types.
  • Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene.
  • Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al . (supra) ; such methods generally involve extended culture in medium containing gradually increasing levels of methotrexate.
  • DHFR-containing expression vectors commonly used for this purpose include pCVSEII-DHFR and pAdD26SV(A) (described in Ausubel et al . , supra) .
  • Any of the host cells described above or, preferably, a DHFR-deficient CHO cell line e.g., CHO DHFRcells, ATCC Accession No.
  • CRL 9096 are among the host cells preferred for DHFR selection of a stably-transfected cell line or DHFR-mediated gene amplification.
  • a number of other selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyl- transferase, and adenine phosphoribosyltransferase genes can be employed in tk, hgprt, or aprt cells, respectively.
  • gpt which confers resistance to mycophenolic acid (Mulligan et al . , Proc. Natl. Acad. Sci .
  • neo which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al . , J. Mol . Biol . 150:1, 1981); and hygro, which confers resistance to hygromycin (Santerre et al . , Gene 30:147, 1981) , can be used.
  • any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed.
  • a system described in Janknecht et al . , Proc. Natl. Acad. Sci. USA, 88 :8972 (1981) allows for the ready purification of non- denatured fusion proteins expressed in human cell lines.
  • the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino- terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ nitriloacetic acid-agarose columns, and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
  • gp49 or a portion thereof can be fused to an immunoglobulin Fc domain.
  • a fusion protein can be readily purified using an affinity column.
  • Gp49 proteins and polypeptides can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees, can be used to generate gp49-expressing transgenic animals. Any technique known in the art can be used to introduce a gp49 transgene into animals to produce the founder lines of transgenic animals.
  • Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al . , Proc. Natl. Acad. Sci., USA 82:6148, 1985); gene targeting into embryonic stem cells (Thompson et al . , Cell 56:313, 1989); and electroporation of embryos (Lo, Mol. Cell. Biol. 3:1803, 1983).
  • the present invention provides for transgenic animals that carry the gp49 transgene in all their cells, as well as animals that carry the transgene in some, but not all of their cells, i.e., mosaic animals.
  • the transgene can be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems
  • the transgene can also be selectively introduced into and activated in a particular cell type (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232, 1992).
  • the regulatory sequences required for such a cell -type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art .
  • the gp49 transgene When it is desired that the gp49 transgene be integrated into the chromosomal site of the endogenous gp49 gene, gene targeting is preferred. Briefly, when such a technique is to be used, vectors containing some nucleotide sequences homologous to an endogenous gp49 gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene also can be selectively introduced into a particular cell type, thus inactivating the endogenous gp49 gene in only that cell type (Gu et al . , Science 265:103, 1984).
  • the expression of the recombinant gp49 gene can be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-PCR. Samples of gp49 gene-expressing tissue, also can be evaluated immunocytochemically using antibodies specific for the gp49 transgene product.
  • gp49 protein Once the recombinant gp49 protein is expressed, it is isolated. Secreted forms can be isolated from the culture media, while non-secreted forms must be isolated from the host cells. Proteins can be isolated by affinity chromatography. In one example, an anti-gp49 protein antibody (e.g., produced as described herein) is attached to a column and used to isolate the gp49 protein. Lysis and fractionation of gp49 protein- harboring cells prior to affinity chromatography can be performed by standard methods (see, e.g., Ausubel et al . , supra) .
  • an anti-gp49 protein antibody e.g., produced as described herein
  • a gp49 fusion protein for example, a gp49-maltose binding protein, a gp49-3- galactosidase, or a gp49-trpE fusion protein
  • gp49 protein isolation see, e.g., Ausubel et al . , supra ; New England Biolabs, Beverly, MA
  • the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography using standard techniques (see, e.g., Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, eds., Work and Burdon, Elsevier, 1980) .
  • Polypeptides of the invention can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed. , 1984 The Pierce Chemical Co., Rockford, IL) . These general techniques of polypeptide expression and purification can also be used to produce and isolate useful gp49 fragments or analogs (described herein) .
  • the invention also features proteins which interact with gp49 and are involved in the function of gp49. Also included in the invention are the genes encoding these interacting proteins. Interacting proteins can be identified using methods known to those skilled in the art.
  • One method suitable method is the "two-hybrid system, " detects protein interactions in vivo (Chien et al . , Proc . Natl . Acad. Sci . USA, 88:9578, 1991) .
  • a kit for practicing this method is available from Clontech (Palo Alto, CA) .
  • Anti-Gp49 Antibodies Human gp49 proteins and polypeptides (or immunogenic fragments or analogs) can be used to raise antibodies useful in the invention; such polypeptides can be produced by recombinant or peptide synthetic techniques (see, e.g., Solid Phase Peptide Synthesis, supra; Ausubel et al . , supra) .
  • the peptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al . , supra , mixed with an adjuvant, and injected into a host mammal.
  • a carrier protein such as KLH, as described in Ausubel et al . , supra
  • Antibodies can be purified by peptide antigen affinity chromatography.
  • various host animals can be immunized by injection with a gp49 protein or polypeptide.
  • Host animals include rabbits, mice, guinea pigs, and rats.
  • Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete) , mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.
  • Antibodies within the invention include monoclonal antibodies, polyclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') 2 fragments, and molecules produced using a Fab expression library.
  • Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, can be prepared using the gp49 proteins described above and standard hybridoma technology (see, e.g., Kohler et al . , Nature 256:495, 1975; Kohler et al . , Eur. J. Immunol. 6:511, 1976; Kohler et al . , Eur. J. Immunol. 6:292, 1976; Hammerling et al . , In Monoclonal Antibodies and T Cell Hybridomas , Elsevier, NY, 1981; Ausubel et al . , supra
  • monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al . , Nature 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al . , Immunology Today 4:72, 1983; Cole et al . , Proc. Natl. Acad. Sci. USA 80:2026, 1983), and the EBV-hybridoma technique (Cole et al . , Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1983).
  • Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • the hybridoma producing the Mab of this invention may be cultivated in vi tro or in vivo .
  • the ability to produce high titers of mAbs in vivo makes this the presently preferred method of production.
  • polyclonal or monoclonal antibodies are tested for specific gp49 recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al . , supra .
  • Antibodies that specifically recognize and bind to gp49 are useful in the invention.
  • such antibodies can be used in an immunoassay to monitor the level of gp49 produced by a mammal (for example, to determine the amount or subcellular location of gp49) .
  • antibodies of the invention are produced using fragments of the gp49 protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues.
  • fragments are generated by standard techniques of PCR, and are then cloned into the PGEX expression vector (Ausubel et al . , supra) . Fusion proteins are expressed in ⁇ coli and purified using a glutathione agarose affinity matrix as described in Ausubel, et al . , supra .
  • each fusion can be injected into at least two rabbits.
  • Antisera can be raised by injections in a series, preferably including at least three booster injections. Antisera is also checked for its ability to immunoprecipitate recombinant gp49 proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase .
  • the antibodies can be used, for example, in the detection of the gp49 in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of gp49. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described to, for example, evaluate the normal and/or engineered gp49- expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a method for inhibiting abnormal gp49 activity. In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al . , Proc. Natl. Acad. Sci., 81:6851, 1984; Neuberger et al .
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine Mab and a human immunoglobulin constant region.
  • Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
  • Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to F(ab') 2 fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab') 2 fragments.
  • Fab expression libraries can be constructed (Huse et al . , Science, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
  • Antibodies to the gp49 can, in turn, be used to generate anti-idiotype antibodies that resemble a portion of gp49 using techniques well known to those skilled in the art (see, e.g., Greenspan et al . , FASEB J. 7:437, 1993; Nissinoff , J. Immunol . 147:2429, 1991) .
  • antibodies that bind to gp49 and competitively inhibit the binding of a ligand of gp49 can be used to generate anti-idiotypes that resemble a ligand binding domain of gp49 and, therefore, bind and neutralize a ligand of gp49.
  • Such neutralizing anti-idiotypic antibodies or Fab fragments of such anti-idiotypic antibodies can be used in therapeutic regimens.
  • Oligonucleotides therapeutic agents can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
  • the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc.
  • the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo) , or agents facilitating transport across the cell membrane (as described, e.g., in Letsinger et al . , Proc. Natl. Acad. Sci. USA 86:6553, 1989; Lemaitre et al., Proc.
  • the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent.
  • the oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5- bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine , xantine, 4-acetylcytosine, 5- (carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethyl-aminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1- methylguanine , 1-methylinosine, 2, 2 -dimethylguanine, 2- methyladenine, 2-methylguanine, 3-methylcytosine, 5- methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2- thiouracil, beta-D
  • the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate , an alkyl phosphotriester, and a formacetal , or an analog of any of these backbones.
  • the oligonucleotide is an ⁇ -anomeric oligonucleotide.
  • An ⁇ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ - units, the strands run parallel to each other (Gautier et al., Nucl. Acids. Res. 15:6625, 1987).
  • the oligonucleotide is a 2 ' -O-methylribonucleotide (Inoue et al . , Nucl. Acids Res. 15:6131, 1987), or a chimeric RNA- DNA analog (Inoue et al . , FEBS Lett.
  • Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.).
  • an automated DNA synthesizer such as are commercially available from Biosearch, Applied Biosystems, etc.
  • phosphorothioate oligonucleotides can be synthesized by the method of Stein et al . (Nucl. Acids Res. 16:3209, 1988), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al . , Proc. Natl. Acad. Sci. USA 85:7448, 1988).
  • the nucleic acid molecules should be delivered to cells that express gp49 in vivo, e.g., brain, heart, kidney, lung, uterus, endothelial cells, fibroblasts, and bone marrow stromal cells.
  • a number of methods have been developed for delivering DNA or RNA to cells; e.g., molecules can be injected directly into the tissue site, or modified molecules, designed to target the desired cells (e.g., linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.
  • a preferred approach uses a recombinant DNA construct in which the oligonucleotide is placed under the control of a strong pol III or pol II promoter.
  • the use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous gp49 transcripts and thereby prevent translation of the gp49 MRNA.
  • a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired RNA.
  • Vectors can be constructed by recombinant DNA technology methods standard in the art .
  • Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.
  • Expression of the sequence encoding the RNA can be by any promoter known in the art to act in mammalian, preferably human cells.
  • Such promoters can be inducible or constitutive.
  • Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist et al .
  • any type of plasmid, cosmid, YAC, or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site; e.g., the brain, heart, kidney, lung, uterus, endothelial cells, fibroblasts, and bone marrow stromal cells.
  • viral vectors can be used that selectively infect the desired tissue (e.g., for brain, herpesvirus vectors may be used) , in which case administration can be accomplished by another route (e.g., systemically) .
  • endogenous gp49 gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the gp49 gene (i.e.. the gp49 promoter and/or enhancers) to form triple helical structures that prevent transcription of the gp49 gene in target cells in the body (Helene Anticancer Drug Des. 6:569, 1981; Helene et al . , Ann. N.Y. Accad. Sci. 660:27, 1992; and Maher, Bioassays 14:807, 1992).
  • the Identification of Proteins which Interact with Gp49 The invention also features proteins which interact with gp49.
  • any method suitable for detecting protein-protein interactions may be employed for identifying transmembrane proteins, intracellular, or extracellular proteins that interact with gp49.
  • traditional methods which may be employed are co- immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates and the use of gp49 to identify proteins in the lysate that interact with the gp49.
  • the gp49 polypetide can be a full length gp49, a soluble extracellular domain of gp49, or some other suitable gp49 polypeptide.
  • such an interacting protein can be identified and cloned and then used, in conjunction with standard techniques, to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of a protein which interacts with the gp49 can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique.
  • the amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding the interacting protein. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known.
  • methods may be employed which result directly in the identification of genes which encode proteins which interact with gp49. These methods include, for example, screening expression libraries, in a manner similar to the well known technique of antibody probing of ⁇ gtll libraries, using labeled gp49 poypeptide or a gp49 fusion protein, e.g., an gp49 polypeptide or domain fused to a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain. There are also methods which are capable of detecting protein interaction.
  • a method which detects protein interactions in vivo is the two-hybrid system (Chien et al . , Proc. Natl . Acad. Sci . USA, 88:9578, 1991) .
  • a kit for practicing this method is available from Clontech (Palo Alto, CA) .
  • plasmids are constructed that encode two hybrid proteins: one plasmid includes a nucleotide sequence encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding gp49, a gp49 polypeptide, or a gp49 fusion protein, and the other plasmid includes a nucleotide sequence encoding the transcription activator protein's activation domain fused to a CDNA encoding an unknown protein which has been recombined into this plasmid as part of a CDNA library.
  • the DNA-binding domain fusion plasmid and the CDNA library are transformed into a strain of the yeast Saccharomyces cerevisiae that contains a reporter gene (e.g., HBS or lacZ) whose regulatory region contains the transcription activator's binding site.
  • a reporter gene e.g., HBS or lacZ
  • the two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product.
  • gp49 may be used as the bait gene product.
  • Total genomic or CDNA sequences are fused to the DNA encoding an activation domain.
  • This library and a plasmid encoding a hybrid of bait gp49 gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene.
  • a bait gp49 gene sequence such as gp49 or a domain of gp49 can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein.
  • These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.
  • a CDNA library of the cell line from which proteins that interact with bait gp49 gene product are to be detected can be made using methods routinely practiced in the art.
  • the CDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4.
  • This library can be co-transformed along with the bait gp49 gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence.
  • a CDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait gp49 gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3 can then be purified from these strains, and used to produce and isolate the bait gp49 gene- interacting protein using techniques routinely practiced in the art.
  • Gp49 proteins and polypeptides and gp49 fusion proteins can be prepared for a wide range of uses including, but not limited to, generation of antibodies, preparation of reagents for diagnostic assays, identification of other molecules involved in inflammation (particularly brain inflammation) , preparation of reagents for use in screening assays for inflammatory modulators, and preparation of therapeutic agents for treatment of inflammation-related disorders.
  • One of the resulting human gp49 cDNAs is a 1.6kb cDNA designated HM18, which predicts a -49.3 kd type 1 integral membrane protein with two C-2 type immunoglobulin superfamily domains and two consensus ITIM motifs in the cytoplasmic domain.
  • HM18 shares 62% nucleotide identity and 47% amino acid identity (57% similarity) with mouse gp49. Similarity is greatest in the first C-2 domain, with 72% nucleotide and 62% amino acid identity (69% similarity) .
  • the ITIM motifs of gp4 (Bl are conserved in HM18.
  • the gene for HM18 is localized to human chromosome 19 (19ql3.4) .
  • RNA blotting and SDS-PAGE immunoblotting reveal transcripts and protein for HM18 in peripheral blood monocytes.
  • HM43 A second cDNA (HM43) was isolated which encodes a 41.6kd protein with four C-2 domains, but no transmembrane or cytoplasmic domains, suggesting that it encodes a soluble form of gp49.
  • ALIGN Comparison of the gp49Bl Amino Acid Sequence with Other Members of the Ig Superfamily. Full-length sequences were aligned with the dynamic programming algorithm of Altschul and Ericson (Altschul et al . , 1986, Bull. Math. Biol. 48:603-616), and a similarity score was derived with the Dayhoff cost matrix (Dayhoff et al . , 1983, Methods Enzymol . 91:524-545), with a cost of 6 for opening a gap (Williams et al . , 1988, Annu. Rev. Immunol. 6:381-405) and an incremental cost of 0.5 for each residue in the gap.
  • the sequence being compared with gp49Bl was then randomized 100 times; and the gp49Bl sequence was aligned with each randomized sequence. The means ⁇ standard deviations of the resulting similarity scores were calculated. To determine the significance of the original comparison, its similarity score was subtracted from the mean score of the randomized comparisons and the result was divided by the standard deviation of the randomized comparisons to obtain the ALIGN score (Altschul et al., 1986, Bull. Math. Biol. 48:603-616). Scores _>3 indicate that the similarities between the compared sequences are significantly greater than would occur by chance alone (Williams et al . , 1988, Annu. Rev. Immunol.
  • gp49A and gp49Bl cDNAs were subjected to PCR with primers whose sequences matched nucleotides 22 to 42 (5 ' -CGAACATTGCCTGGACTCACC- 3'; 5' untranslated region) and 1288 to 1309 (5'- GTTTCTCATTAGATGACTTG-3' ; 3' untranslated region) that are common to the gp49A and gp49Bl cDNAs (Castells et al . , 1994, J. Biol. Che. 269:8393-8401).
  • the 5' ends of the upstream and downstream primers contained X al and BamHI linkers, respectively, to facilitate ligation into the mammalian expression vector, pMH-NEO (Hahn et al . , 1993, Gene 127:267-268).
  • PCR was performed for 30 cycles with primer annealing at 60°C.
  • DH5 ⁇ bacterial cells (Stratagene, La Jolla, CA) were transformed either with pMH-NEO alone or with pMH-NEO containing gp49A cDNA or gp49Bl cDNA.
  • Plasmid DNA containing the vector alone or with the inserted cDNAs was purified with Nucleobond AX (The Nest Group, Southborough, MA) and introduced into P815 cells by electroporation with 200 mV and 960 ⁇ farads in a BioRad Gene Pulser Electroporator . Stable transfectants were selected by their resistance to 1.2 mg/ml G418.
  • gp49Bl transfectants were stained with mAb B23.1 and F(ab') 2 fragments of fluorescein isothiocyanate (FITC) -labeled goat anti-rat IgM (Jackson Im unoresearch, Avondale, PA) .
  • the cells were sorted, and the 1% brightest cells were collected and cloned by being seeded in 96-well plates at an average density of 0.3 cells/well. After 7 days, the plates in which cells were growing in fewer than 30% of the wells were analyzed by flow cytometry for binding of mAb B23.1.
  • gp49A transfectants Five clones exhibited similar or stronger staining with mAb B23.1 compared with BMMC, and one such clone (1-11G) was chosen for study.
  • total RNA was isolated from stable P815 clones that had been transfected with gp49A cDNA, and the presence of gp49A transcripts was detected by reverse transcriptase (RT) - PCR.
  • RT reverse transcriptase
  • a downstream primer located in exon 6 of gp49A was used (5' -TAGCCTTATTTTTGTGACGAC-3 ' ) .
  • PCR was performed on the resultant cDNAs with the same downstream primer plus an upstream primer from exon 3 of gp49A (5' -ACCAAGTTCAAAATTCGATTT-3 ' ) ; an annealing temperature of 60 °C was used for 40 cycles.
  • These primers were specific for gp49A because they generated a product by RT-PCR from COS-7 cells transiently transfected with a gp49A, but not gp49Bl, cDNA (data not shown) .
  • rat IgE anti-dinitrophenyl hapten (clone LO-DNP-30) was obtained from Zymed (South San Francisco, CA) .
  • Rat IgM mAb B23.1 anti-mouse gp49Bl and rat IgM mAb RATNP 17.3 were purified by affinity chromatography from ascites produced in BALB/c nu/nu mice as described (Katz et al . , 1989, J. Immunol. 142:919-926).
  • a synthetic peptide (CEVPLENRNKTKFKIRF ; prepared at the Brigham and Women's Hospital Protein Microsequencing Laboratory) was synthesized corresponding to amino acids 72 - 81 of the extracellular domain of gp49A; this peptide differs from the sequence of gp49Bl at the underlined amino acids (Castells et al . , 1994, J. Biol. Chem. 269:8393-8401). The amino-terminal cysteine is not found in the gp49A amino acid sequence but was added to facilitate coupling to carrier protein.
  • the peptide (2 mg) was coupled to 2 mg of maleimide-activated keyhole limpet hemocyanin (Imject Kit; Pierce, Rockford IL) .
  • the conjugate 125 ⁇ g in 250 ⁇ l phosphate-buffered saline [PBS], pH 7.2
  • PBS phosphate-buffered saline
  • the conjugate 125 ⁇ g in 250 ⁇ l phosphate-buffered saline [PBS], pH 7.2
  • PBS phosphate-buffered saline
  • DytRx Co., Norcross, GA Hunter's Titermax adjuvant emulsion
  • a booster immunization consisting of 100 ⁇ g of each peptide conjugate and the same adjuvant was administered 3 weeks later and 2 wk after the booster immunization blood was collected.
  • the titer of the antiserum was determined by ELISA.
  • Peptides (10 ⁇ g in PBS, pH 7.5) were incubated for 1 h at room temperature in 96-well Immulon II plates (Dynatech Labs, Ch . antilly, VA) .
  • the wells were washed 3 times with PBS, blocked by incubation with 1% bovine serum albumin (BSA) in PBS (BSA/PBS) for 1 h at room temperature, washed 3 times with 1% Tween 20 in PBS (TPBS) , and incubated with serial dilutions of rabbit serum in 1% BSA/PBS for 1 h at room temperature.
  • BSA bovine serum albumin
  • the wells were washed 5 times with TPBS, incubated for 1 h at room temperature with a 1:2000 dilution of horseradish peroxidase-labeled goat-anti -rabbit IgG (Biorad, Hercules, CA) in 1% BSA/PBS, washed 6 times with TPBS, and incubated for 20 min at room temperature with 100 ⁇ l of a 200 ⁇ g/ml solution of 2 , 2 ' -Azino-di- [3 - ethylbenzythiazolinsulfonate] (Boehringer-Mannheim, Indianapolis, IN) containing 0.015% hydrogen peroxide in citrate buffer, pH 4.25.
  • Absorbance at 405 nm was measured on a Titertek Multiscan MCC/340 plate reader.
  • Half-maximal binding of anti-gp49A 72 . B7 serum to the immunizing peptide occurred at an -1200-fold dilution of serum.
  • the reactivity of anti-gp49A 72 . 87 serum with a peptide consisting of a cysteine plus gp49Bl amino acids 72-87 (CQVPLETRNKAKFNIPS) was -10% of its reactivity with the immunizing peptide, as defined by reactivity with dilutions of the serum.
  • Anti-gp49 72 _ 87 Ig was purified on peptide affinity columns. Each peptide (10 mg) was coupled to 1 mg cyanogen bromide-activated Sepharose 4B (Pharmacia-LKB Biotechnology, Piscataway, NJ) , according to the manufacturer's protocol. An 8-ml sample of anti-gp49 72 . 87 serum was applied to a column containing 2 ml of resin coupled with the heterologous gp49Bl 72 _ S7 peptide, and the flow-through was applied to a column containing the homologous peptide.
  • the second column was washed sequentially with 20 column volumes of 10 mM Tris-HCl, pH 7.5; 20 column volumes of 500 mM NaCl in 10 mM Tris-HCl, pH 7.5; and 20 column volumes of 10 mM Tris-HCl, pH 7.5.
  • Ig was then eluted with 2 column volumes of 100 mM glycine, pH 2.5 into 0.2 -column volumes of 1 M Tris-HCl, pH 8.0 and was dialyzed twice against PBS, pH 7.2.
  • Non- immune Ig was purified on a Protein A-Sepharose column with the same steps described above. Flow Cytometric Analyses.
  • the cells were then incubated for 30 min at 4°C, washed by centrifugation in cold H/B/A, and incubated for 30 min at 4°C in a saturating concentration of FITC-labeled F(ab') 2 fragments of goat anti-rat IgM ( ⁇ chain specific) .
  • FITC-labeled F(ab') 2 fragments of goat anti-rat IgM ⁇ chain specific
  • mBMMC (1 x 10 7 /ml) were incubated for 1 h at 4°C in 50% WCM containing mAb B23.1 or RATNP 17.3 (20 ⁇ g/ml each), rat IgE (3.25 ⁇ /ml) , rat IgE + RATNP, or rat IgE + dilutions of mAb B23.1. After being washed once by centrifugation at 4°C, replicate cell pellets were resuspended on ice at their original volume with 50% WCM either alone or containing 25 ⁇ g/ml F(ab') 2 mouse IgG anti-rat IgG (heavy and light chain reactive) (Jackson Immunoresearch) .
  • the cells were then incubated for 15 min at 37°C with agitation, and 50- ⁇ l samples were removed from each tube in duplicate and diluted with an equal volume of 0.15 M EDTA in HBSS.
  • the cells were sedimented by centrifugation at 250 g for 5 min at 4°C, the supernatants were decanted and retained, and the pellets were resuspended to their original volumes with a 1:1 (v/v) mixture of 5% WCM/0.15 M EDTA and sonicated on ice.
  • 3-hexosaminidase was quantitated in a 30 ⁇ l sample of each supernatant and pellet in duplicate by spectrophotometric analysis of the hydrolysis of p-nitrophenyl -
  • the percent release values for each experimental condition were calculated by the formula [S/ (S + P) ] x 100, where S and P are the mediator contents of the samples of each supernatant and cell pellet, respectively.
  • the net percent release values were obtained by subtracting the percent release of sensitized cells incubated in 50% WCM alone from that of replicate cells challenged with F(ab') 2 mouse IgG anti-rat IgG heavy and light chains. LTC 4 release was measured by radioimmunoassay (PerSeptive Diagnostics, Cambridge, MA) as described (Katz et al . , 1992, J. Immunol. 148:868-871).
  • gp49Bl was compared by ALIGN analysis, used previously to define gp49A and gp49Bl as members of the Ig superfamily (Arm et al . , 1991, J. Biol. Chem. 266- 15966-15973; and Castells et al . , 1994, J. Biol. Chem. 269:8393-8401), with receptors of the Ig superfamily that like gp49Bl possess two C2 type, Ig-like domains.
  • the cytoplasmic domain of gp49Bl contains two sequences that conform to the ITIM core consensus (Olcese et al . , 1996, J. Immunol. 156:4531- 4534), namely, IVYAQV and VTYAQL (Castells et al . , 1994, J. Biol. Chem. 269:8393-8401).
  • mBMMC were incubated at 4°C with rat IgE (3.25 ⁇ g/ml) alone or together with the RATNP 17.3 isotype control (20 ⁇ g/ml) or incremental concentrations of mAb B23.1 (0.625 to 20 ⁇ g/ml). Samples of cells were also incubated with RATNP 17.3 or mAb B23.1 alone. The cells were washed once and incubated for 15 min at 37°C in medium either alone or with the coligating antibody, a F(ab') 2 mouse IgG that is reactive with the light chains of rat IgE- and IgM.
  • gp49 molecules might be inhibitory proteins initially arose from ALIGN analysis of the amino acid sequences of gp49Bl versus other members of the Ig superfamily containing two C2-type, Ig- like domains. This analysis revealed statistically significant homology between gp49Bl and human KIRs . There was also homology between gp49Bl, human FcotR, and bovine
  • Fc ⁇ 2R but not with other Fc ⁇ R species or FceRI of the human and mouse.
  • the segregation of the homologous proteins into a distinct family was supported by separate evolutionary tree analysis (Thompson et al . , 1994, Nucleic Acids Research 22:4673-4680; and Felsenstein, J. , 1989, Cladistics 5:164).
  • a second finding suggested a basis for a function for gp49Bl, namely, suppression of an activation event in mast cells, because the cytoplasmic domain possessed two ITIMs, a motif that is also recognized in Fc ⁇ RIIb species and in KIRs of NK cells and T lymphocyte subsets.
  • mouse Fc ⁇ RIIbl contains only one ITIM
  • coligation of this Fc receptor with the B lymphocyte antigen receptor or with FceRI inhibits B lymphocyte and mast cell activation, respectively (Muta et al., 1994, Nature 368:70-73; D'Ambrisio et al . , 1995, Science 268-293-297; and Daeron et al . , 1995, J. Clin. Invest. 95:577-585).
  • mouse gp49Bl does not exhibit statistically significant amino acid sequence homology with mouse Fc ⁇ RIIbl.
  • mAb B23.1 recognizes cell surface gp49Bl, but not gp49Bl after exposure to SDS, mAb B23.1 appears to recognize a conformation-dependent, gp49Bl-specific epitope within an extracellular domain that is 89% identical to that of gp49A.
  • the latter finding is pronounced of the fact that certain anti- hu an KIR mAbs specifically recognize individual receptor species, even though their extracellular domains differ only by several scattered amino acids (Wagtmannet al . , 1995, Immunity 2:439-449).
  • gp49Bl contains two core ITIM motifs and suppresses secretory granule and lipid-derived mediator release when coligated with FceRI leads us to propose that gp49Bl be designated "mouse mast cell inhibitory receptor" (mMIR) .
  • mMIR mouse mast cell inhibitory receptor
  • the mechanism by which ITIMs inhibit cellular activation events appears to be through the downstream recruitment of one or more tyrosine phosphatases that reverse a tyrosine phosphorylation step(s) critical to progressive signal transduction.
  • Coligation of the B lymphocyte antigen receptor with Fc ⁇ RIIbl causes tyrosine phosphorylation of each receptor with different resultant intracellular protein associations.
  • the B lymphocyte antigen receptor associates with syk kinase via the receptor's immunoreceptor tyrosine-containing activation motif in the Ig- ⁇ and Ig-S subunits (Muta et al .
  • ITIMs may mediate inhibitory effects by recruiting tyrosine phosphatases that could reverse and/or suppress tyrosine phosphorylation events at one or more steps of signal transduction cascades that activate cellular functions.
  • mMIR is homologous to members of the Ig superfamily that bind other members of the superfamily (e.g., . Fc receptors/Ig, KIRs/MHC class I) suggests that its counterligand may also be a member of the Ig superfamily.
  • mouse NK cells express a family of KIRs (Ly49) that contain the ITIM motif (Olcese et al . , 1996, J. Immunol. 156:4531-4534) and function like human NK cell KIRs in interacting with MHC class I molecules
  • the Ly49 family consists of type II transmembrane proteins with an extracellular C-type lectin domain rather than an Ig-like structure (Yokoyama et al . , 1995, Seminars in Immunology 7:89-101). It is possible therefore, based on the structural and functional considerations presented here, that mMIR may belong to a family of molecules that are the mouse equivalents of human NK and T lymphocyte KIRs.
  • the cytosolic tyrosine phosphatase SHP-1 (formerly termed protein tyrosine phosphatase [PTP] 1C and hematopoietic cell phosphatase) coimmunoprecipitates with Fc ⁇ RIIbl only when the receptor is phosphorylated on tyrosine after coligation.
  • PTP protein tyrosine phosphatase
  • a phosphorylated, but not non-phosphorylated, peptide matching this region of Fc ⁇ RIIbl binds SHP-1 from B lymphocyte lysates in equal quantities whether the cells are unstimulated, stimulated, or stimulation- inhibited .
  • phosphorylation of the Fc ⁇ RIIbl motif is critical to the • binding of SHP-1.
  • phosphorylated Fc ⁇ RIIbl may both recruit and regulate the activity of SHP-1.
  • signal transduction leading to the activation of B lymphocytes requires tyrosine kinase phosphorylation of multiple substrates, coligation of Fc ⁇ RIIbl with the B lymphocyte antigen receptor may promote the intracellular dephosphorylation of one or more substrates critical to activation signaling.
  • Fc ⁇ RIIbl or the alternative splicing variant Fc ⁇ RIIb2 with FceRI on mouse bone marrow-derived mast cells results in the downregulation of exocytosis elicited through FceRI (Daeron et al . , 1995, J. Clin. Invest. 95:577-585).
  • mBMMC mouse bone marrow-derived mast cells
  • NK cells and T lymphocyte subsets express a group of Ig superfamily cell surface receptors, termed "killer cell inhibitory receptors" (KIRs) that recognize allelic groups of the major histocompatibility complex (MHC) class I molecules (Moretta et al . , 1996, Annu. Rev. Immunol. 14:619-648; Lanier et al . , 1996, Immunol Today 17:86-91; Moretta et al . , 1994, Advances in Immunology 55:341-380; Yokoyama et al . , 1995, Seminars in Immunology 7:89-101; and Gumperz et al . , 1995, Nature 378:245-248).
  • KIRs killer cell inhibitory receptors
  • ITIM immunoreceptor tyrosine-based inhibition motif
  • Phosphorylated, but not non-phosphorylated, peptides containing ITIMs from KIR cytoplasmic domains interact with and stimulate SHP-1 activity (Burshtyn et al . , 1996, Immunity 4:77-85; and Olcese et al . , 1996, J. Immunol. 156:4531-4534).
  • SHP-1 activity Burshtyn et al . , 1996, Immunity 4:77-85; and Olcese et al . , 1996, J. Immunol. 156:4531-4534.
  • the transfection of cytolytic, KIR-deficient NK cells exhibiting low levels of SHP-1 with constructs encoding a KIR and active SHP-1 inhibits their cytotoxicity for an appropriate target cell, whereas cotransfection with a construct encoding the KIR and enzymatically inactive SHP-1 does not.
  • the amino acid sequence of gp49Bl bears statistically significant homologies to human KIRs and to two Fc receptors,- human Fc receptors for IgA (Fc ⁇ R) and bovine Fc receptors for IgG2 (Fc ⁇ 2R) , that together form a newly recognized family within the Ig superfamily. This family does not include Fc ⁇ RIIb or the other Fc ⁇ R of mouse or human origin.
  • Fc ⁇ R human Fc receptors for IgA
  • Fc ⁇ 2R bovine Fc receptors for IgG2
  • gp49 By ALIGN comparison of the amino acid sequence of gp49's with numerous receptors of the Ig superfamily, a newly recognized family has been established that includes gp49, the human myeloid cell Fc receptor for IgA, the bovine myeloid cell Fc receptor for IgG2 , and the human killer cell inhibitory receptors (KIRs) expressed on natural killer (NK) cells and T lymphocyte subsets.
  • KIRs human killer cell inhibitory receptors expressed on natural killer (NK) cells and T lymphocyte subsets.
  • NK natural killer cells and T lymphocyte subsets.
  • cytoplasmic domain of gp49Bl contains two immunoreceptor tyrosine-based inhibition motifs (ITIMs) that are also present in KIRs; these motifs downregulate NK cell and T cell activation signals that lead to cytotoxic activity.
  • ITIMs immunoreceptor tyrosine-based inhibition motifs
  • mAb B23.1 was shown to recognize only gp49Bl.
  • Coligation of mAb B23.1 bound to gp49Bl and IgE fixed to the high affinity Fc receptor for IgE (FceRI) on the surface of mouse bone marrow-derived mast cells inhibited exocytosis in a dose- related manner, as defined by the release of the secretory granule constituent j ⁇ -hexosaminidase, as well as the generation of the membrane-derived lipid mediator, leukotriene C4.
  • gp49Bl is an endogenous, ITIM- containing integral cell surface protein that downregulates FceRI-mediated release of proinflammatory mediators from mast cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Les mastocytes de souris expriment la protéine gp49B1, un élément de surface cellulaire de la superfamille de l'immunoglobuline (Ig) codé par le gène gp49B. On décrit une famille humaine de gp46, avec établissement d'un nouveau trajet transmembranaire à action contre-régulatrice permettant d'inhiber l'activation des mastocytes.
PCT/US1997/015586 1996-09-06 1997-09-05 INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49 WO1998009638A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44103/97A AU4410397A (en) 1996-09-06 1997-09-05 Inhibition of mast cell activation by gp49-based mechanisms and reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2584696P 1996-09-06 1996-09-06
US60/025,846 1996-09-06

Publications (1)

Publication Number Publication Date
WO1998009638A1 true WO1998009638A1 (fr) 1998-03-12

Family

ID=21828368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015586 WO1998009638A1 (fr) 1996-09-06 1997-09-05 INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49

Country Status (2)

Country Link
AU (1) AU4410397A (fr)
WO (1) WO1998009638A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048017A1 (fr) * 1997-04-24 1998-10-29 Immunex Corporation Famille d'immunoregulateur appeles recepteurs des leucocytes, ressemblant a l'immunoglobuline
WO2000029431A1 (fr) * 1998-11-17 2000-05-25 Tanox, Inc. Reticulation de molecules bispecifiques du motif d'activation a base de tyrosine des immunorecepteurs avec le motif d'inhibition a base de tyrosine des immunorecepteurs, dans un but therapeutique
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
WO2003064662A1 (fr) * 2001-03-16 2003-08-07 Tanox, Inc. Molecules bispecifiques reticulant itim et itam pour le traitement des allergies
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
US7834157B2 (en) 1997-04-24 2010-11-16 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US20120321623A1 (en) * 2004-09-03 2012-12-20 The Trustees Of Columbia University In The City Of New York ILT3 Polypeptides and Uses Thereof
EP3573647B1 (fr) * 2017-01-27 2023-04-05 Immatics Biotechnologies GmbH Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. BIOL. CHEM., 18 March 1994, Vol. 269, No. 11, CASTELLS M.C. et al., "Cloning of the gp49B Gene of the Immunoglobulin Superfamily and Demonstration that One of Its Two Products is An Early-Expressed Mast Cell Surface Protein Originally Discribed as gp49", pages 8393-8401. *
J. BIOL. CHEM., 25 August 1991, Vol. 266, No. 24, ARM J.P. et al., "Molecular Cloning of gp49, A Cell-Surface Antigen that is Preferentially Expressed by Mouse Mast Cell Progenitors and is a New Member of the Immunoglobulin Superfamily", pages 15966-15973. *
J. IMMUNOL., 01 February 1989, Vol. 142, No. 3, KATZ H.R. et al., "Activation- and Phorbol Ester-Stimulated Phosphorylation of a Plasma Membrane Glycoprotein Antigen Expressed on Mouse IL-3-Dependent Mast Cells and Serosal Mast Cells", pages 919-926. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875703B2 (en) 1997-04-24 2011-01-25 Immunex Corporation LIR-9, a novel leukocyte immunoglobulin-like receptor
US8058397B2 (en) 1997-04-24 2011-11-15 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US7014853B2 (en) 1997-04-24 2006-03-21 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US7834157B2 (en) 1997-04-24 2010-11-16 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
WO1998048017A1 (fr) * 1997-04-24 1998-10-29 Immunex Corporation Famille d'immunoregulateur appeles recepteurs des leucocytes, ressemblant a l'immunoglobuline
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
WO2000029431A1 (fr) * 1998-11-17 2000-05-25 Tanox, Inc. Reticulation de molecules bispecifiques du motif d'activation a base de tyrosine des immunorecepteurs avec le motif d'inhibition a base de tyrosine des immunorecepteurs, dans un but therapeutique
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
EP1772515A1 (fr) 1999-05-12 2007-04-11 Immunex Corporation Immunorégulateur de la famille nommée 'récepteurs semblables à des récepteurs de leucocytes de type immunoglobuline' (LIR)
WO2003064662A1 (fr) * 2001-03-16 2003-08-07 Tanox, Inc. Molecules bispecifiques reticulant itim et itam pour le traitement des allergies
US20120321623A1 (en) * 2004-09-03 2012-12-20 The Trustees Of Columbia University In The City Of New York ILT3 Polypeptides and Uses Thereof
US9150635B2 (en) * 2004-09-03 2015-10-06 The Trustees Of Columbia University In The City Of New York ILT3 polypeptides and uses thereof
EP3573647B1 (fr) * 2017-01-27 2023-04-05 Immatics Biotechnologies GmbH Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers

Also Published As

Publication number Publication date
AU4410397A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
EP1210425B2 (fr) Recepteur de baff (bcma) et agent immunoregulateur
JP3703834B2 (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
JP4855513B2 (ja) 哺乳動物細胞膜タンパク質；関連試薬
US7659093B2 (en) DAP12 nucleic acids
CZ2000490A3 (cs) Interleukin-18-vazebné proteiny, příprava a použití
US20070065875A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
HU226787B1 (en) A tumor necrosis factor related ligand
AU2002325333A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
WO1998009638A1 (fr) INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49
US20040110218A1 (en) BMOG, a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for immunomodulatory purposes
US5807714A (en) Method of production of antigen-specific glycosylation inhibiting factor
ES2301164T3 (es) Slam, antigeno coestimulador de la superficie de celulas t.
US20040241807A1 (en) Interleukin-1 related gene and protein
CA2384115C (fr) Techniques et compositions destinees au traitement de maladie inflammatoire par utilisation d'agents de modulation cadherine-11
ZA200201201B (en) BAFF receptor (BCMA), an immunoregulatory agent.
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512901

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载